• Age 18\

⁃ 75 years old, both male and female

• Stage 1: pathologically diagnosed, incurable NSCLC subjects who have failed standard treatment

• Stage 2: have a histologically or cytologically confirmed diagnosis of relapsed or metastatic NSCLC; have not received prior systemic treatment for their recurrent or metastatic NSCLC; PD-L1 TPS \<50% as confirmed by central laboratory

• At least one measurable lesion based on RECIST v1.1 criteria

• ECOG PS score: 0-1 points

• Expected survival period ≥ 3 months

• Good levels of organ function

• Patients voluntarily joined the study and signed informed consent